Skip to content
MarketScale
‹ Back to IndustriesHealthcare

How Community-Based Hospitals Can Remain Independent and Continue to Serve

If you feel like there are fewer community hospitals today than there used to be, it’s not just your imagination. Statistics show that in 1975 there were 7,156 hospitals in the U.S.; today that number has fallen to under 5,600 facilities. While the American Hospital Association classifies 4,840 of these as community hospitals, many may still be affiliated with…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

If you feel like there are fewer community hospitals today than there used to be, it’s not just your imagination. Statistics show that in 1975 there were 7,156 hospitals in the U.S.; today that number has fallen to under 5,600 facilities. While the American Hospital Association classifies 4,840 of these as community hospitals, many may still be affiliated with a larger network or system. Very few community hospitals are true standalone, independent facilities. Which begs the question, in an increasingly volatile healthcare marketplace, is further decline in the number of hospitals imminent, and are those standalone independents at risk of becoming obsolete? Let’s take a look.

Community hospitals have a deep connection with the regions they serve. Local businesspeople sit on the board, the hospital CEO speaks regularly at the Chamber of Commerce, and the hospital is the hub of healthcare services in the surrounding area. An academic medical center can serve an entire region, and a healthcare network can blanket many states, but a true community hospital is firmly committed to the locality it serves. A well-functioning community hospital epitomizes patient-centered care and commands patient loyalty by fostering a partnership with its physicians.

But without some important changes, these community hospitals are in danger of disappearing. Paul H. Keckley, PhD notes in his Keckley Report that inpatient care is shrinking at the same time competition in outpatient services is intensifying. Clinical innovations are driving up annual costs for drugs, technologies, and devices used in hospitals at a higher rate than the reimbursement by payers. Essential safety net and public health programs, such as Medicare and Medicaid, are cutting their rates at the very same time demand for services is increasing – especially among the neediest in small, rural communities.

It’s clear that standalone community hospitals will continue to face a number of challenges in the years ahead. However, they often don’t have the in-house resources that a larger system or network might have to help them adapt to the changing circumstances and environment. Fortunately, there are innovative ways for them to stay independent and remain a vibrant part of their community. One of the best moves they can make is to partner with like-minded facilities through a collaborative organization like TPC.

TPC provides the framework for independent, community-based hospitals to achieve system value through standardization, utilization, and pricing strategies that optimize operational, financial, and clinical performance. Through our unique collaborative model, TPC Members realize results that are typically only achieved by large health systems. We maintain strong partnerships and develop innovative solutions that allow our Members to leverage economies of scale to help control costs and increase value within Supply Chain, Purchased Services and Revenue Cycle – ultimately driving down the cost of healthcare for patients.

While many uncertainties will continue to plague the healthcare industry, providers do have opportunities to work together to combat threats and remain successful. By becoming a TPC Member and collaborating with similar organizations, community-based hospitals do not have to become obsolete, but can continue to thrive for years to come.

Stronger Together. Superior Results.

Learn more about becoming a TPC Member at http://www.tpc1.com/members.

Read more at tpc1.com

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512